C5 and age-related macular degeneration: Basel, Switzerland), another C5 inhibitor approved for other complement-mediated disorders, for treatment of GA secondary to AMD (NCT01255462) and uveitis (NCT01526889) did not result in significant amelioration of pathology regardless of intravenous or intravitreal delivery, and further trials were not pursued after phase 2 trials were completed [148].